Tag: management

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools.

CALGARY, Alberta, June 24, 2025 (GLOBE NEWSWIRE) -- FLINT Corp. (“FLINT”) (TSX: FLNT) is pleased to announce that all matters presented for approval at its annual meeting (the "Meeting") of holders of common shares ("Common Shares") held earlier today were approved. A total of 24,877,170 Common Shares, representing approximately 22.62% of the issued and outstanding Common Shares, were represented at the Meeting.

Toronto, June 24, 2025 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Fund (CBOE:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.